Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung
Status:
Terminated
Trial end date:
2018-09-26
Target enrollment:
Participant gender:
Summary
Patients with advanced or metastatic, gpNMB-expressing Squamous Cell Carcinoma (SCC) of the
lung who have failed a prior platinum-based chemotherapy regimen will receive glembatumumab
vedotin.
Glembatumumab vedotin consists of an antibody (a type of human protein) attached to a drug
called Monomethyl Auristatin E (MMAE) that can kill cancer cells. Glembatumumab vedotin is
intended to work by specifically directing the drug to the cancer cell. It attaches to a
molecule on the cancer cell called gpNMB, and then releases the MMAE inside the tumor cell,
which in turn causes the cell to die.
The purpose of this study is to see whether glembatumumab vedotin is effective in treating
people who have advanced or metastatic squamous cell lung cancer that contains gpNMB, to
examine how the body handles the drug and the side effects associated with glembatumumab
vedotin.